Kyverna Therapeutics (KYTX) Cash & Equivalents (2023 - 2026)
Kyverna Therapeutics' Cash & Equivalents was $31.81 million in Q2 2026, down 40.5% from $53.44 million a year earlier and down 1.2% from the prior quarter.
Powered by 
Analysis
Kyverna Therapeutics (KYTX) Cash & Equivalents (2023 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Kyverna Therapeutics came in at $124.09 million, up 28.4% from FY2024.
- In earlier years, Cash & Equivalents was $96.62 million in FY2024 (+178.9%) and $34.65 million in FY2023.
- The Q2 2026 figure marks the lowest quarterly Cash & Equivalents since Q3 2023.
- Compared with a year earlier, Cash & Equivalents was higher in three of the last eight quarters, with growth averaging 34.7%.
- The best year-over-year quarter for Cash & Equivalents over five years was Q1 2024 (growth of 463.7%); the worst was Q1 2025 (a decline of 74.6%).
- Per Business Quant data, KYTX's Cash & Equivalents in the three quarters before Q2 2026 was $32.19 million (Q1 2026), $124.09 million (Q4 2025) and $34.16 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Kyverna Therapeutics | 382.97 Mn | 382.97 Mn | - | 31.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.81 Mn |
| Mar 31, 2026 | 32.19 Mn |
| Dec 31, 2025 | 124.09 Mn |
| Sep 30, 2025 | 34.16 Mn |
| Jun 30, 2025 | 53.44 Mn |
| Mar 31, 2025 | 56.87 Mn |
| Dec 31, 2024 | 96.62 Mn |
| Sep 30, 2024 | 104.66 Mn |
| Jun 30, 2024 | 131.62 Mn |
| Mar 31, 2024 | 224.29 Mn |
| Dec 31, 2023 | 34.65 Mn |
| Sep 30, 2023 | 22.97 Mn |
| Jun 30, 2023 | 53.43 Mn |
| Mar 31, 2023 | 39.79 Mn |
API Access
Kyverna Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=KYTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "KYTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=KYTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();